SURPASS trial programme (revision 1)
Old revision·09:00, 21 Jul 2024·DataTableDunja
This is an old revision of this page, as it stood at 09:00, 21 Jul 2024, saved by DataTableDunja with the summary start article; endpoints and registration only. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| SURPASS trial programme | |
|---|---|
| Drug | Tirzepatide 5, 10 and 15 mg weekly |
| Indication | Type 2 diabetes |
| Notable member | SURPASS-2, head-to-head with semaglutide |
| Topic infobox · conventions | |
The SURPASS trial programme is the phase 3 series that established tirzepatide for type 2 diabetes. Its trials compared tirzepatide at 5, 10 and 15 mg weekly against placebo, semaglutide 1 mg, insulin degludec, insulin glargine and dulaglutide.[1]
Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.[1]